Edwards Lifesciences Gets a Buy Rating from Cowen & Co.

By Jason Carr

In a report issued on October 9, Josh Jennings from Cowen & Co. reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), with a price target of $135. The company’s shares closed yesterday at $110.47.

According to TipRanks.com, Jennings is a 2-star analyst with an average return of 0.0% and a 53.3% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Corindus Vascular Robotics, Boston Scientific Corp, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Edwards Lifesciences is Strong Buy and the average price target is $135.56, representing a 22.7% upside.

In a report issued on September 27, SunTrust Robinson also reiterated a Buy rating on the stock with a $146 price target.

The company has a one-year high of $121.45 and a one-year low of $81.12. Currently, Edwards Lifesciences has an average volume of 1.27M.

Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2017, Donald Bobo, the CVP, Heart Valve Therapy of EW sold 25,000 shares for a total of $2,900,000.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Edwards Lifesciences Corp. engages in the design, development, manufacture, and markets products to treat stage cardiovascular disease. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World.